

Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** – specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

Report Contents

1. April Approval Results/Updates
2. Companies with Expected PDUFA Dates in the Next Three Months
3. Expected PDUFA Dates by Sector
4. May Drug Candidates
5. June Drug Candidates
6. July Drug Candidates
7. Price and Financial Info

Copyright 2006 by Revere Data, LLC. All rights reserved.

Notes:

- a) Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
- b) Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

Principals or employees of Revere Data may have a position in, and may from time to time purchase or sell, securities of any company discussed in this report.

For more information on Revere's independent research data and investment analytics, please click [here](#) or contact us as follows:

Revere Data, LLC | 2 Rector Street, Suite 900 | New York, NY 10006
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

1. April Approval Results/Updates

Company (Symbol)	Drug Candidate	Indication	Previous Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Approval Results/Update
Discovery Laboratories (DSCO)	Surfaxin (Lucinactant)	Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants	4/05/2006	Surfactants	Approvable Letter received on 4/05/2006
Alkermes, Inc. (ALKS) / Cephalon, Inc. (CEPH)	Medisorb Vivitrol (Naltrexone)	Alcohol Dependence	<i>4/17/2006</i>	Opioid Antagonists	Approved by FDA on 4/13/2006
Noven Pharmaceuticals, Inc. (NOVN) / Shire plc (SHPGY)	Daytrana (Methylphenidate)	Attention Deficit Hyperactivity Disorder (ADHD)	4/19/2006	Dopamine Receptor Blocking Agents	Approved by FDA on 4/06/2006
Cephalon, Inc. (CEPH)	Nuvigil (Armodafinil)	Excessive Sleepiness Associated with Narcolepsy, Shift Work Sleep Disorder, and Obstructive Sleep Apnea/Hypopnea Syndrome	4/28/2006	Alpha Adrenergic Receptor Agonists	Result Pending
Genzyme Corporation (GENZ)	Myozyme (Alpha-Glucosidase)	Pompe Disease	4/28/2006	Enzyme Replacement Therapy	Approved by FDA on 4/28/2006
Pfizer Inc. (PFE)	Genotropin (Recombinant Human Growth Hormone)	Short Stature and Growth Problems Associated with Turner's Syndrome	<i>April 2006</i>	Growth Hormones	Result Pending
Salix Pharmaceuticals Ltd (SLXP)	MoviPrep (formerly NRL944)	Bowel Cleansing Prior to Colonoscopy, Intestinal Surgery and Barium Enema X-Ray Examinations	<i>April 2006</i>	Hyperosmotic Agents	Approvable Letter received on 4/10/2006.
Cephalon, Inc. (CEPH)	Sparlon (Modafinil)	Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents Aged 6 to 17	<i>April 2006</i>	Alpha Adrenergic Receptor Agonists	Cephalon has disclosed a new PDUFA date on 8/22/2006

* Dates in **bold** indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. Dates in *italics* indicate Revere estimates based on NDA (New Drug Approval) submission dates.


























2. Companies with Expected PDUFA Dates in the Next Three Months

May	June	July
Bristol Myers Squibb Co. (BMY)	Biogen Idec Inc (BIIB)	AstraZeneca PLC (AZN)
CollaGenex Pharmaceutical, Inc (CGPI)	BioMarin Pharmaceutical (BMRN)	AVANIR Pharmaceuticals (AVNR)
Cubist Pharmaceuticals, Inc. (CBST)	Bristol Myers Squibb Co. (BMY)	Barrier Therapeutics, Inc. (BTRX)
DOV Pharmaceutical, Inc. (DOVP)	Celgene Corporation (CELG)	Johnson & Johnson (JNJ) [2]
Johnson & Johnson (JNJ)	Cellegy Pharmaceuticals, Inc. (CLGY)	MedImmune, Inc. (MEDI)
King Pharmaceuticals (KG)	Cephalon, Inc. (CEPH)	
Merck & Co., Inc. (MRK)	DOV Pharmaceutical, Inc (DOVP)	
MGI Pharma, Inc. (MOGN)	Eli Lilly & Co. (LLY)	
Novartis AG (NVS)	Elan Corporation, plc (ELN)	
Neurocrine Biosciences, Inc. (NBIX)	Endo Pharmaceuticals (ENDP) [2]	
Pfizer Inc. (PFE) [2]	Genentech, Inc. (DNA)	
sanofi-aventis (SNY) [2]	GlaxoSmithKline plc (GSK) [2]	
Shire plc (SHPGY)	Johnson & Johnson (JNJ)	
SuperGen, Inc. (SUPG)	Merck & Co., Inc. (MRK)	
Wyeth (WYE)	Neurocrine Biosciences, Inc. (NBIX)	
	Novartis AG (NVS)	
	Penwest Pharmaceuticals (PPCO)	
	Pfizer Inc. (PFE)	
	POZEN Inc. (POZN)	
	Roche Holding Ltd. (RHHBY)	
	sanofi-aventis (SNY) [2]	
	Schering-Plough Corp (SGP)	
Total Companies = 15	Total Companies = 22	Total Companies = 5

Notes:

1. Some drug candidates are filed jointly by two companies.
2. Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].
3. Click the company name to view the NDA (New Drug Approval) Filed drug candidates for the company in [Revere Research](#).

3. Expected PDUFA Dates by Sector*

May	June	July
*Healthcare  Biopharmaceuticals [12]  Cardiovascular System [1]  Dermatology [1]  Endocrinology/Metabolism [1]  Hematology [1]  Infectious Diseases [3]  Neurology [2]  Pain Management [1]  Toxicology [1]  Urology [1]	*Healthcare  Biopharmaceuticals [16]  Cardiovascular System [1]  Digestive System [1]  Infectious Diseases [3]  Neurology [3]  Oncology [3]  Ophthalmology [1]  Pain Management [3]  Respiratory System [1]	*Healthcare  Biopharmaceuticals [6]  Dermatology [2]  Infectious Diseases [1]  Neurology [1]  Pain Management [1]  Respiratory System [1]
Total PDUFA Dates = 12	Total PDUFA Dates = 16	Total PDUFA Dates = 6

* Based on Revere's [proprietary classification system](#).

4. May Drug Candidates

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2nd FDA Approved Drug of the Company?
DOV Pharmaceutical, Inc. (DOVP) / Neurocrine Biosciences, Inc. (NBIX) / Pfizer Inc. (PFE)	Indiplon Immediate Release Capsule	Primary (Chronic) and Transient Insomnia	5/15/2006	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	Yes	No—Multiple	Yes (DOVP) / Yes (NBIX) / No (PFE)
MGi Pharma, Inc. (MOGN) / SuperGen, Inc. (SUPG)	Dacogen (Decitabine)	Myelodysplastic Syndrome (MDS)	5/15/2006	Pyrimidine Analogs	Yes	Yes—Vidaza (PHRM)	No
Bristol Myers Squibb Co. (BMY) / sanofi-aventis (SNY)	Plavix (Clopidogrel Bisulfate)	Acute ST-Segment Elevation Myocardial Infarction	5/18/2006	Adenosine Diphosphate (ADP) Inhibitors	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
King Pharmaceuticals (KG) / Wyeth (WYE)	Altace (Ramipril)	Delaying the Progression of Chronic Kidney Disease In Hypertensive, Non-Diabetic Patients	5/22/2006	Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2nd FDA Approved Drug of the Company?
Merck & Co., Inc. (MRK)	Zostavax	Herpes Zoster (Shingles) Vaccine, Prevention of Postherpetic Neuralgia (PHN), Reduction of Acute and Chronic Shingles-Associated Pain in Adults	5/25/2006	Herpes Zoster (Shingles) Vaccines	No	Yes—Only Drug Candidate with This PMOA for This Indication	No
Shire plc (SHPGY)	Elaprase (Idursulfase)	Hunter Syndrome (Mucopolysaccharidosis II)	5/25/2006	Enzyme Replacement Therapy	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Sanofi-aventis (SNY)	Pentacel	Combination Vaccine for Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib) in Children	<i>5/25/2006</i>	Bacterial/Viral Vaccines	Yes	Yes—Infranrix HeXa-HepB-IPV/Hib (GSK)	No
Johnson & Johnson (JNJ)	ALZA lonsys (E-Trans Fentanyl)	Management of Acute Post-Operative Pain	<i>5/29/2006</i>	Opioids	Yes	No—Multiple	No
CollaGenex Pharmaceutical, Inc (CGPI)	Oracea (Doxycycline Hyclate Modified Release)	Rosacea	5/31/2006	Tetracycline	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Pfizer Inc. (PFE)	Champix (Varenicline)	Smoking Cessation	<i>May 2006</i>	Nicotinic Receptor Agonists	Yes	No—Multiple	No
Novartis AG (NVS)	Exelon (Rivastigmine Tartrate)	Mild to Moderate Dementia Associated with Parkinson's Disease	<i>May 2006</i>	Acetylcholinesterase Inhibitors	Yes	**Yes—Only Drug Candidate with This PMOA for This Indication	No
Cubist Pharmaceuticals (CBST)	Intravenous Cubicin (Daptomycin)	Bacteremia with Known or Suspected Endocarditis Caused by Staphylococcus aureus	<i>5/27/2006</i>	Lipopeptides	Yes	Yes—Vancocin HCl I.V. (LLY)	Yes

* Dates in **bold** indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. Dates in *italics* indicate Revere estimates based on NDA (New Drug Approval) submission dates.

**Pfizer's Donepezil Hydrochloride is in Phase 3 trial for treating general Dementia, not specific to Parkinson's Disease.

5. June Drug Candidates

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2nd FDA Approved Drug of the Company?
BioMarin Pharmaceutical (BMRN)	Orapred ODT (Prednisolone Sodium Phosphate)	Severe Asthma	6/1/2006	Steroidal Anti-Inflammatory Drugs (SAID)	Yes	No—Multiple	No
sanofi-aventis (SNY)	Multaq (Dronedarone)	Atrial Fibrillation	June 2006	Sodium Channel Blocking Agents/ Potassium Channel Blocking Agents	Yes	No-Multiple	No
Merck & Co., Inc. (MRK) / sanofi-aventis (SNY)	Gardasil	Human Papillomavirus (HPV) Vaccine, Cervical Cancer Vaccine	6/8/2006	Papillomavirus Vaccines	No	Yes—Cervarix (GSK)	No
GlaxoSmithKline plc (GSK) / POZEN Inc. (POZN)	Trexima (Naproxen/ Sumatriptan)	First-Line Therapy for Migraine Headaches	6/8/2006	Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists	No	Yes—Only Drug Candidate with This PMOA for This Indication	No (GSK) / Yes (POZN)
GlaxoSmithKline plc (GSK)	Hycamtin (Topotecan Hydrochloride)	Recurrent or Persistent Cervical Cancer not Amenable to Curative Treatment with Surgery and/or Radiation Therapy	6/15/2006	Topoisomerase I Inhibitors	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Endo Pharmaceuticals (ENDP) / Penwest Pharmaceuticals (PPCO)	EN3202 (Oxymorphone Hydrochloride Extended-Release)	Moderate-to-Severe Pain	6/22/2006	Opioids	Yes	No-Multiple	No (ENDP) / Yes (PPCO)
Endo Pharmaceuticals (ENDP)	EN3203 (Oxymorphone Hydrochloride Immediate-Release)	Moderate-to-Severe Pain	6/22/2006	Opioids	Yes	No-Multiple	No
Schering-Plough Corp. (SGP)	Noxafil (Posaconazole)	Prophylaxis of Serious Invasive Fungal Infections in High Risk Patients	6/22/2006	Imidazoles	Yes	Yes—Nizoral (JNJ)	No
Johnson & Johnson (JNJ)	TMC 114	Human Immunodeficiency Virus (HIV)	6/23/2006	Protease Inhibitors	Yes	No-Multiple	No

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2 nd FDA Approved Drug of the Company?
DOV Pharmaceutical, Inc. (DOVP) / Neurocrine Biosciences, Inc. (NBIX) / Pfizer, Inc. (PFE)	Indiplon Modified Release Tablet	Primary (Chronic) and Transient Insomnia	6/27/2006	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	Yes	No-Multiple	Yes (DOVP) / Yes (NBIX) / No (PFE)
Biogen Idec Inc (BIIB) / Elan Corporation, plc (ELN)	Tysabri (Natalizumab)	Relapsing Forms of Multiple Sclerosis (MS)	6/28/2006	Alpha 4 Integrin Inhibitors	No	Yes—Only Drug Candidate with This PMOA for This Indication	No
Bristol Myers Squibb Co. (BMY)	Dasatinib (Src/AbL Kinase Inhibitor)	Chronic Myelogenous Leukemia (CML)	6/28/2006	Tyrosine Kinase Inhibitors	Yes	Yes—Gleevec/Glivec (NVS)	No
Celgene Corporation (CELG)	Revlimid (Lenalidomide)	Relapsed/ Refractory Multiple Myeloma	6/30/2006	Immunomodulatory Agents	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No
Roche Holding Ltd. (RHHBY) / Novartis AG (NVS) / Genentech, Inc. (DNA)	Lucentis (Ranibizumab)	Wet Age-Related Macular Degeneration (AMD)	6/30/2006	Vascular Endothelial Growth Factor Inhibitors (VEGF)	Yes	Yes—Macugen (PFE, OSIP, NKTR, ENZN)	No
Cephalon, Inc. (CEPH)	Cima Labs OraVescent Fentanyl	Management of Breakthrough Pain in Patients with Cancer	6/30/2006	Opioids	Yes	No-Multiple	No
Cellegy Pharmaceuticals, Inc. (CLGY)	Cellegesic (Nitroglycerin)	Pain Associated with Anal Fissures/ Treatment of Anal Fissures	<i>6/30/2006</i>	Vasodilatory Agents	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	Yes

* Dates in **bold** indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. Dates in *italics* indicate Revere estimates based on NDA (New Drug Approval) submission dates.

6. July Drug Candidate

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2 nd FDA Approved Drug of the Company?
Johnson & Johnson (JNJ)	Remicade (Infliximab)	Moderate to Severe Plaque Psoriasis	<i>7/07/2006</i>	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	Yes	Yes—Enbrel (AMGN), Humira (ABT)	No
MedImmune Inc. (MEDI)	Cold Adapted Influenza Vaccine-Trivalent (CAIV-T)	Influenza (Flu) Vaccine in Healthy Individuals 5 to 49 Years of Age	<i>7/19/2006</i>	Influenza (Flu) Vaccine	Yes	No—Multiple	No

Company (Symbol)	Drug Candidate	Indication	Expected PDUFA Date*	Primary Mechanism of Action (PMOA)	Proven PMOA?	If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication?	1st or 2nd FDA Approved Drug of the Company?
AstraZeneca Inc. (AZN)	Symbicort pMDI (Formoterol/Budesonide)	Maintenance Treatment of Asthma	7/24/2006	Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)	Yes	No—Multiple	No
AVANIR Pharmaceuticals (AVNR)	Neurodex (Dextromethorphan/Quinidine Sulfate)	Pseudobulbar Affect (Emotional Lability)	7/28/2006	Antitussives/Sodium Channel Blocking Agents	No	Yes	Yes
Barrier Therapeutics, Inc. (BTRX)	Sebazole (Ketoconazole)	Seborrheic Dermatitis	July 2006	Imidazoles	Yes	Yes—Loprox (MRX), Nizoral (JNJ)	No
Johnson & Johnson (JNJ)	TetraPeel	Local Anesthetic Prior to Surgery	July 2006	Opioids	Yes	Yes—Only Drug Candidate with This PMOA for This Indication	No

* Dates in **bold** indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. Dates in *italics* indicate Revere estimates based on NDA (New Drug Approval) submission dates.

7. Price and Financial Info

Data as of April 27, 2006

Company (Symbol)	Last Price	Market Cap. (M)	30-Day Avg. Volume	Price/Book	Total Debt/Equity (MRQ)	Cash & Equivalents + Short-Term Investments (MRQ) (M)	1-Year Return	Relative Performance vs. Revere Biopharm Index	Institutional Holdings (Subscribers Only)	Options Available ?	
May	Bristol Myers Squibb (BMY)	25.27	50,113	6,604,728	4.41	0.77	5,799	-0.70%	-23.08%	●	YES
	CollaGenex Pharmaceutical, (CGPI)	12.19	212	126,233	6.50	0.00	44	185.88%	163.50%	●	YES
	Cubist Pharmaceuticals (CBST)	22.45	1,228	782,128	70.82	9.95	102	157.05%	134.67%	●	YES
	DOV Pharmaceutical (DOVP)	8.12	189	1,114,894	-9.76	N/A	98	-47.71%	-70.09%	●	NO
	Johnson & Johnson (JNJ)	58.65	174,249	8,835,704	4.55	0.07	16,138	-13.46%	-35.84%	●	YES
	King Pharmaceuticals (KG)	17.35	4,229	1,694,395	2.14	0.17	525	119.90%	97.52%	●	YES
	Merck & Co., Inc. (MRK)	34.60	75,540	8,702,214	4.20	0.45	15,638	2.22%	-20.16%	●	YES
	MGI Pharma, Inc. (MOGN)	18.32	1,450	1,008,058	13.35	2.42	129	-18.11%	-40.49%	●	YES
	Neurocrine Biosciences, Inc. (NBIX)	58.60	2,137	705,925	5.48	0.15	273	66.25%	43.87%	●	YES
Novartis AG (NVS)	56.81	119,224	1,077,182	3.59	0.26	10,933	20.42%	-1.96%	●	YES	

	Pfizer Inc. (PFE)	24.86	183,989	23,323,848	2.81	0.27	22,736	-6.22%	-28.60%	●	YES
	sanofi-aventis (SNY)	46.13	132,311	1,077,191	2.43	0.24	1,892	6.45%	-15.93%	●	YES
	Shire plc (SHPGY)	46.55	7,880	486,143	4.11	0.00	844	50.45%	28.07%	●	YES
	SuperGen, Inc. (SUPG)	5.32	281	764,184	4.38	0.00	48	35.41%	13.03%	●	YES
	Wyeth (WYE)	48.57	65,283	4,782,192	5.35	0.77	8,235	10.71%	-11.67%	●	YES
June	Biogen Idec Inc (BIIB)	44.96	15,531	3,207,474	2.20	0.01	851	26.15%	3.77%	●	YES
	BioMarin Pharmaceutical (BMRN)	12.47	1,054	1,239,454	N/A	N/A	49	109.12%	86.74%	●	YES
	Bristol Myers Squibb Co. (BMY)	25.27	50,093	6,604,728	4.41	0.77	5,799	-0.74%	-23.12%	●	YES
	Celgene Corporation (CELG)	42.39	14,596	4,094,472	21.82	0.63	724	121.69%	99.31%	●	YES
	Cellegy Pharmaceuticals, Inc. (CLGY)	0.65	20	306,085	-3.03	-0.80	2	-67.00%	-89.38%	●	NO
	Cephalon, Inc. (CEPH)	65.36	3,938	2,318,113	6.19	2.77	484	48.26%	25.88%	●	YES
	DOV Pharmaceutical, Inc. (DOVP)	8.12	189	1,114,894	N/A	N/A	98	-47.71%	-70.09%	●	YES
	Elan Corporation, plc (ELN)	14.46	6,274	3,274,436	372.84	119.36	1,102	211.94%	189.56%	●	YES
	Eli Lilly & Co. (LLY)	52.75	59,866	4,309,220	5.73	0.60	5,038	-8.66%	-31.04%	●	YES
	Endo Pharmaceuticals (ENDP)	31.37	4,174	1,160,448	4.55	0.00	584	58.99%	36.61%	●	YES
	Genentech, Inc. (DNA)	79.58	83,853	3,924,704	10.95	0.28	2,365	13.64%	-8.74%	●	YES
	GlaxoSmithKline plc (GSK)	55.45	160,545	1,164,223	12.14	0.89	9,364	14.11%	-8.27%	●	YES
	Johnson & Johnson (JNJ)	58.65	174,308	8,835,704	4.55	0.07	16,138	-13.43%	-35.81%	●	YES
	Merck & Co., Inc. (MRK)	34.60	75,497	8,702,214	4.20	0.45	15,638	2.16%	-20.22%	●	YES
	Neurocrine Biosciences, Inc. (NBIX)	58.60	2,132	705,925	5.47	0.15	273	65.88%	43.50%	●	YES
	Novartis AG (NVS)	56.81	119,370	1,077,182	3.60	0.26	10,933	20.57%	-1.81%	●	YES
	Penwest Pharmaceuticals (PPCO)	20.11	448	285,241	7.45	0.00	55	52.42%	30.04%	●	YES
	Pfizer Inc.	24.86	184,136	23,323,848	2.81	0.27	22,736	-6.14%	-28.52%	●	YES
	POZEN Inc. (POZN)	14.91	436	315,595	11.75	0.00	46	116.67%	94.29%	●	YES

	Roche Holding Ltd. (RHHBY)	76.30	131,627	N/A	4.85	0.28	16,265	26.32%	3.94%	●	NO
	sanofi-aventis (SNY)	46.13	132,283	1,077,191	2.43	0.24	1,892	6.43%	-15.95%	●	YES
	Schering-Plough Corp. (SGP)	19.26	28,510	5,346,304	4.52	0.41	5,122	-5.96%	-28.34%	●	YES
July	AstraZeneca PLC (AZN)	55.01	87,200	1,024,164	6.39	0.09	6,065	26.74%	4.36%	●	YES
	AVANIR Pharmaceuticals (AVNR)	11.74	370	603,556	9.68	0.02	48	1.72%	-20.66%	●	NO
	Barrier Therapeutics, Inc. (BTRX)	9.43	228	103,778	3.00	0.01	78	-44.74%	-67.12%	●	NO
	Johnson & Johnson (JNJ)	58.65	174,308	8,835,704	4.55	0.07	16,138	-13.43%	-35.81%	●	YES
	MedImmune, Inc. (MEDI)	31.57	7,815	2,717,262	4.99	0.32	1,472	23.70%	1.32%	●	YES